Hansa Biopharma (Exclusive Rights to Sell Idefirix in Europe, Middle East And North Africa) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Buyout/​LBO

  • Financing Rounds
  • 1

Hansa Biopharma (Exclusive Rights to Sell Idefirix in Europe, Middle East And North Africa) General Information

Description

The kidney transplant drug development rights in Europe, the Middle East, and North Africa. The medicine is a first-in-class treatment that specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies within 2 to 6 hours.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Private Equity-Backed
Corporate Office
  • Sweden
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Acquirer
SERB Pharmaceuticals
Corporate Office
  • Sweden

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hansa Biopharma (Exclusive Rights to Sell Idefirix in Europe, Middle East And North Africa) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Hansa Biopharma (Exclusive Rights to Sell Idefirix in Europe, Middle East And North Africa)‘s full profile, request access.

Request a free trial

Hansa Biopharma (Exclusive Rights to Sell Idefirix in Europe, Middle East And North Africa) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Hansa Biopharma (Exclusive Rights to Sell Idefirix in Europe, Middle East And North Africa)‘s full profile, request access.

Request a free trial

Hansa Biopharma (Exclusive Rights to Sell Idefirix in Europe, Middle East And North Africa) FAQs

  • Where is Hansa Biopharma (Exclusive Rights to Sell Idefirix in Europe, Middle East And North Africa) headquartered?

    Hansa Biopharma (Exclusive Rights to Sell Idefirix in Europe, Middle East And North Africa) is headquartered in Sweden.

  • What industry is Hansa Biopharma (Exclusive Rights to Sell Idefirix in Europe, Middle East And North Africa) in?

    Hansa Biopharma (Exclusive Rights to Sell Idefirix in Europe, Middle East And North Africa)’s primary industry is Buildings and Property.

  • Is Hansa Biopharma (Exclusive Rights to Sell Idefirix in Europe, Middle East And North Africa) a private or public company?

    Hansa Biopharma (Exclusive Rights to Sell Idefirix in Europe, Middle East And North Africa) is a Private company.

  • What is the current valuation of Hansa Biopharma (Exclusive Rights to Sell Idefirix in Europe, Middle East And North Africa)?

    The current valuation of Hansa Biopharma (Exclusive Rights to Sell Idefirix in Europe, Middle East And North Africa) is .

  • What is Hansa Biopharma (Exclusive Rights to Sell Idefirix in Europe, Middle East And North Africa)’s current revenue?

    The current revenue for Hansa Biopharma (Exclusive Rights to Sell Idefirix in Europe, Middle East And North Africa) is .

  • Who are Hansa Biopharma (Exclusive Rights to Sell Idefirix in Europe, Middle East And North Africa)’s investors?

    Hansa Biopharma has invested in Hansa Biopharma (Exclusive Rights to Sell Idefirix in Europe, Middle East And North Africa).

  • When was Hansa Biopharma (Exclusive Rights to Sell Idefirix in Europe, Middle East And North Africa) acquired?

    Hansa Biopharma (Exclusive Rights to Sell Idefirix in Europe, Middle East And North Africa) was acquired on 01-Jul-2026.

  • Who acquired Hansa Biopharma (Exclusive Rights to Sell Idefirix in Europe, Middle East And North Africa)?

    Hansa Biopharma (Exclusive Rights to Sell Idefirix in Europe, Middle East And North Africa) was acquired by SERB Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process